Not checkedNot checked for notices yet.
Pancreatic ductal adenocarcinoma: the role of circulating tumor DNA
Joseph R. Habib, MD, Lingdi Yin, MD, Jun Yu, MD, PhD
Journal of Pancreatology · 2019
doi:10.1097/jp9.0000000000000021 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers in humans, and utilized treatments over the past decades have shown little evidence of improvement in survival. This lack of progress in PDAC treatment outcomes has largely been attributed to a variety of limitations in all phases of care. These limitations most notably include late diagnosis leading to limited treatment options and consequently poorer response to treatments and eventual outcomes. Clinical implications regarding the emergence of circulating tumor cells and DNA (ctDNA) have shown promise in augmenting each step in the management of PDAC. This paper will review the emergence of ctDNA and its value in detection of common PDAC DNA alterations, potential clinical implications and utility, followed by the current limitations and the next steps that need to be taken to translate its use into a standard of care.
Abstract licence: CC BY-NC-ND
References55
40 more references, whose wording the paper’s licence keeps private.
All 55 referencesReads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.